1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (011) 91 04428254180
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
The role of nitric oxide synthases and nitrotyrosine in retinoblastoma
Article first published online: 7 MAR 2005
DOI: 10.1002/cncr.20961
Copyright © 2005 American Cancer Society
Additional Information
How to Cite
Adithi, M., Nalini, V. and Krishnakumar, S. (2005), The role of nitric oxide synthases and nitrotyrosine in retinoblastoma. Cancer, 103: 1701–1711. doi: 10.1002/cncr.20961
Publication History
- Issue published online: 4 APR 2005
- Article first published online: 7 MAR 2005
- Manuscript Accepted: 16 DEC 2004
- Manuscript Revised: 27 NOV 2004
- Manuscript Received: 2 JUN 2004
Funded by
- Indian Council for Medical Research. Grant Numbers: reference 5/4/6/6/2003-2004-NCD-II, Iris code 2003-000810
REFERENCES
- 1, . Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 1999; 36: 8–18.
- 2
- 3, , , . Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology. 1991; 98: 1425–1431.
- 4, , , . Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996; 114: 1339–1343.
- 5, , , et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996; 114: 1348–1356.
- 6, , , et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996; 114: 1321–1328; erratum in Arch Ophthalmol. 1997; 115: 525.
- 7, , , , , . Thermo chemotherapy in hereditary retinoblastoma. Br J Ophthalmol. 2003; 87: 90–95.
- 8, , , et al. Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. Arch Ophthalmol. 2002; 120: 607–612.
- 9, , , . Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors. Arch Ophthalmol. 1999; 117: 365–370.
- 10, , , , . Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. Arch Ophthalmol. 1996; 114: 1396–13401.
- 11, , , . Toxicity and dose-response studies of 1,25-(OH) 2-16-ene-23-yne vitamin D3 in transgenic mice. Clin Cancer Res. 1998; 4: 2253–2256.
- 12, , , et al. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology. 1997; 229: 283–291.
- 13, , , , , . Mutant herpes simplex virus-mediated suppression of retinoblastoma. Curr Eye Res. 1999; 18: 321–326.
- 14, , , , , . Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther. 1999; 10: 441–448.
- 15, , , et al. EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci. 2004; 45: 4247–4250.
- 16, . Cytokine induced apoptosis in human retinoblastoma cells. Mol Vis. 2004; 10: 315–322.
- 17, , , et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995; 82: 4392–4396.
- 18, . The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373–376.
- 19, , . Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327: 524–526.
- 20, , . Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43: 109–142.
- 21, . Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem. 1994; 63: 175–195.
- 22, . Nitric oxide synthases in mammals. Biochem J. 1994; 298: 249–258.
- 23, . Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. 1995; 57: 707–736.
- 24, , , et al. Nitric oxide synthase in human gynecological cancer. Cancer Res. 1994; 54: 1352–1354.
- 25, , , et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995; 72: 41–44.
- 26, , , , , . Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002; 95: 1902–1910.Direct Link:
- 27, , , et al. Expression of inducible nitric oxide synthase in cutaneous adnexal tumours of the head and neck. Int J Oral Maxillofac Surg. 2003; 32: 534–538.
- 28, , , et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol. 2003; 162: 793–801.
- 29, , . Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002; 47: 1–16.
- 30, , , et al. Nitric oxide synthase immunoreactivity in human bladder carcinoma. Mol Pathol. 2001; 54: 248–252.
- 31, , . Nitric oxide: a review of its role in retinal function and disease. Vision Res. 1996; 36: 2979–2994.
- 32, . Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat Res. 1995; 339: 73–89.
- 33, . Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev. 1998; 17: 77–89.
- 34. Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia. Leukemia. 2000; 14: 1685–1694.
- 35, , , , , . Nitric oxide involvement in tumor-induced immunosuppression. J Immunol. 1994; 152: 5077–5083.
- 36, , , . Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res. 1991; 51: 2531–2535.
- 37, , , . Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA. 1994; 91: 9407–9411.
- 38, , , , . Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 1994; 54: 789–793.
- 39, , , et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med. 1995; 181: 1333–1343.
- 40, , , , , . Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst. 1997; 89: 421–427.
- 41, , , et al. Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. Hum Gene Ther. 1998; 9: 845–854.
- 42, , , , , . Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA. 1993; 90: 9813–9817.
- 43, , , , , . Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol. 1994; 111: 894–902.
- 44, , , . Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 1991; 51: 6073–6078.
- 45. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995; 38: 105–128.
- 46, , , . Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood. 1992; 80: 1880–1884.
- 47, . Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev. 1998; 17: 39–53.
- 48, , , et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995; 92: 4392–4396.
- 49, , , . Bacterial lipopolysaccharide antagonizes transforming growth factor β1-induced apoptosis in primary cultures of hepatocytes. Hepatology. 1996; 23: 1200–1207.
- 50, , , , et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene. 1997; 15: 771–779.
- 51, , , , , . Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA. 1998; 95: 8823–8828.
- 52, . Nitric oxide synergistically enhances DNA strand breakage induced by polyhydroxyaromatic compounds, but inhibits that induced by the Fenton reaction. Arch Biochem Biophys. 1997; 342: 13–21.
- 53, , , . Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center. J Pediatr Ophthalmol Strabismus. 2003; 40: 265–267.
- 54, , , et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol. 2000; 157: 1405–1412.
- 55, , , , . nm23 expression in retinoblastoma. Ocul Immunol Inflamm. 2004; 12: 127–135.
- 56, , , , , . Tetraspanin protein KAI1 expression in retinoblastoma. Br J Ophthalmol. 2004; 88: 593–595.
- 57, , , . Prognostic significance of Fas expression in retinoblastoma. Ocul Immunol Inflamm. 2003; 11: 107–113.
- 58, , , et al. Expression of Fas ligand in retinoblastoma. Cancer. 2004; 101: 1672–1676.Direct Link:
- 59, , , et al. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma. Cancer. 2004; 100: 1059–1069.Direct Link:
- 60, , , et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004; 88: 1521–1526.
- 61, . Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 1998; 17: 107–118.
- 62, , , , , . Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol. 1998; 186: 306–312.Direct Link:
- 63, , . Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996; 63: 511–518.
- 64, , . Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun. 1995; 206: 15–21.
- 65, , , . Matrix metalloproteinases in retinoblastoma: correlation with metastatic behavior [abstract 1421]. Invest Ophthalmol Vis Sci. 2003; 44: E-1421.
- 66. Inactivated tumor suppressor Rb by NO promotes mitosis in human breast cancer cells. J Cell Biochem. 2004; 92: 1–5.Direct Link:
- 67, , , . Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther. 2003; 2: 815–823.